April 09, 2020 04:00 PM Eastern Daylight Time ROCKVILLE, Md. & PROVIDENCE, R.I. & GOLDEN, Colo.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study ...
- Meeting on ITI-1001 Phase I program for treatment of Newly-Diagnosed Glioblastoma (GBM) - March 03, 2020 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately held ...
Nov. 20, 2019 ROCKVILLE, MD – Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that Duane Mitchell, MD, ...
November 04, 2019 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that ...
Immunomic Therapeutics to Present at the First International Symposium on Merkel Cell Carcinoma 2019
Data demonstrates that UNITE, as a nucleic acid platform, elicits potent immune responses ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. will present data on its investigational nucleic acid platform, UNITE (UNiversal ...
Discussion of UNITE platform as applied in cancer immunotherapy BOSTON--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today a presentation at the Precision Lung Cancer World R&D Summit in Boston. On Tuesday, ...
- ITI-1000 targets CMV with Immunomic Therapeutics’ immunotherapy UNITE™ platform - ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) ...
ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed brain tumor expert E. Antonio ‘Nino’ Chiocca, M.D., Ph.D., Harvey W. ...
July 12, 2019 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as ...
June 20, 2019 20:05 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the promotion of Teri Heiland, Ph.D. to Chief Scientific Officer. ...
May 30, 2019 04:05 PM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the China ...
Immunomic Therapeutics to Participate at Sachs’ 5th Annual Immuno-Oncology BD&L and Investment Forum
May 24, 2019 20:05 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 5th Annual Immuno-oncology ...